Drug intelligence / Profile preview

Megaper

Development stage: Unknown
Lead developer: AS Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**Megaper** is an oral fixed-dose capsule marketed by AS Pharmaceutical for neuropathic pain. It contains **pregabalin 75 mg** and **methylcobalamin 750 micrograms**. Pregabalin binds the alpha-2-delta auxiliary subunit of voltage-gated calcium channels, reducing release of excitatory neurotransmitters involved in neuropathic pain signaling; methylcobalamin is an active vitamin B12 cofactor that supports myelin synthesis and neuronal metabolic function. ([aspharma.org](https://aspharma.org/future-products))

Brand names: Megaper

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on Megaper.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Megaper.

Explore the full profile